Cargando…
Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449874/ https://www.ncbi.nlm.nih.gov/pubmed/32094465 http://dx.doi.org/10.1038/s41375-020-0770-8 |
| _version_ | 1783574708583661568 |
|---|---|
| author | Locatelli, Franco Whitlock, James A. Peters, Christina Chen-Santel, Christiane Chia, Victoria Dennis, Robyn M. Heym, Kenneth M. Katz, Aaron J. Kelsh, Michael A. Sposto, Richard Tu, Huakang Tuglus, Catherine A. Verma, Anupam Vinti, Luciana Wilkes, Jennifer J. Zubarovskaja, Nathalya Zugmaier, Gerhard von Stackelberg, Arend Sun, Weili |
| author_facet | Locatelli, Franco Whitlock, James A. Peters, Christina Chen-Santel, Christiane Chia, Victoria Dennis, Robyn M. Heym, Kenneth M. Katz, Aaron J. Kelsh, Michael A. Sposto, Richard Tu, Huakang Tuglus, Catherine A. Verma, Anupam Vinti, Luciana Wilkes, Jennifer J. Zubarovskaja, Nathalya Zugmaier, Gerhard von Stackelberg, Arend Sun, Weili |
| author_sort | Locatelli, Franco |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7449874 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74498742020-09-02 Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia Locatelli, Franco Whitlock, James A. Peters, Christina Chen-Santel, Christiane Chia, Victoria Dennis, Robyn M. Heym, Kenneth M. Katz, Aaron J. Kelsh, Michael A. Sposto, Richard Tu, Huakang Tuglus, Catherine A. Verma, Anupam Vinti, Luciana Wilkes, Jennifer J. Zubarovskaja, Nathalya Zugmaier, Gerhard von Stackelberg, Arend Sun, Weili Leukemia Letter Nature Publishing Group UK 2020-02-24 2020 /pmc/articles/PMC7449874/ /pubmed/32094465 http://dx.doi.org/10.1038/s41375-020-0770-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter Locatelli, Franco Whitlock, James A. Peters, Christina Chen-Santel, Christiane Chia, Victoria Dennis, Robyn M. Heym, Kenneth M. Katz, Aaron J. Kelsh, Michael A. Sposto, Richard Tu, Huakang Tuglus, Catherine A. Verma, Anupam Vinti, Luciana Wilkes, Jennifer J. Zubarovskaja, Nathalya Zugmaier, Gerhard von Stackelberg, Arend Sun, Weili Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia |
| title | Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia |
| title_full | Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia |
| title_fullStr | Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia |
| title_full_unstemmed | Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia |
| title_short | Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia |
| title_sort | blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory ph-negative b-cell precursor acute lymphoblastic leukemia |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449874/ https://www.ncbi.nlm.nih.gov/pubmed/32094465 http://dx.doi.org/10.1038/s41375-020-0770-8 |
| work_keys_str_mv | AT locatellifranco blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT whitlockjamesa blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT peterschristina blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT chensantelchristiane blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT chiavictoria blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT dennisrobynm blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT heymkennethm blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT katzaaronj blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT kelshmichaela blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT spostorichard blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT tuhuakang blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT tugluscatherinea blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT vermaanupam blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT vintiluciana blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT wilkesjenniferj blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT zubarovskajanathalya blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT zugmaiergerhard blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT vonstackelbergarend blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia AT sunweili blinatumomabversushistoricalstandardtherapyinpediatricpatientswithrelapsedrefractoryphnegativebcellprecursoracutelymphoblasticleukemia |